Anti-angiogenic drug discovery: lessons from the past and thoughts for the future

Bibliography

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Gimbrone MA Jr, Leapman SB, Cotran RS, et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136(2):261-76
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13(1):31-6
   PubMed Web of Science ®Google Scholar
• Tseng PL, Tai MH, Huang CC, Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol 2008;98(5):349-57
   PubMed Web of Science ®Google Scholar
• Yuan A, Lin CY, Chou C.H, Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS One 2011;6(1):e16062
   PubMedGoogle Scholar
• Jacobsen J, Grankvist K, Rasmuson T, Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int 2006;97(5):1102-8
   PubMed Web of Science ®Google Scholar
• Koch S, Tugues S, Li X, Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011;437(2):169-83
   PubMed Web of Science ®Google Scholar
• Liu W, Xu J, Wang M, Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol 2011;39(5):1213-20
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Pallares J, Montero-Conde C, Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 2010;17(1):7-16
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298-308
   PubMed Web of Science ®Google Scholar
• Staton CA, Kumar I, Reed MW, Neuropilins in physiological and pathological angiogenesis. J Pathol 2007;212(3):237-48
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-4
   PubMed Web of Science ®Google Scholar
• Folkman J. Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res 2006;312(5):594-607
   PubMed Web of Science ®Google Scholar
• Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007;13(4):1098-106
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 2011;5:117-29
   PubMedGoogle Scholar
• Friedman HS, Prados MD, Wen PY, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740-5
   PubMed Web of Science ®Google Scholar
• Goel S, Duda DG, Xu L, Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91(3):1071-121
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52(2):237-68
   PubMed Web of Science ®Google Scholar
• Teicher BA. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics –> mechanism(s) of interaction). Cancer Metastasis Rev 1996;15(2):247-72
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12(3):356-61
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27(8):1227-34
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(20):3239-47
   PubMed Web of Science ®Google Scholar
• Robert NJ, Dieras V, Glaspy J, RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-60
   PubMed Web of Science ®Google Scholar
• Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009;122(4):322-8
   PubMed Web of Science ®Google Scholar
• Armstrong TS, Wen PY, Gilbert MR, Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol 2012. PMID 22307472. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Schulz J, McCleod M, Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23(16):3697-705
   PubMed Web of Science ®Google Scholar
• Zhu X, Wu S, Dahut WL, Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49(2):186-93
   PubMed Web of Science ®Google Scholar
• Miles D, Bridgewater J, Ellis P, Using bevacizumab to treat metastatic cancer: UK consensus guidelines. Br J Hosp Med (Lond) 2010;71(12):670-7
   PubMed Web of Science ®Google Scholar
• Hang XF, Xu WS, Wang JX, Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011;67(6):613-23
   PubMed Web of Science ®Google Scholar
• Burudpakdee C, Zhao Z, Munakata J, Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies. J Med Econ 2012;5(2):371-7
   Google Scholar
• Scappaticci FA, Fehrenbacher L, Cartwright T, Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91(3):173-80
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sheldon H, Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clin Cancer Res 2009;15(22):7069-76
   PubMed Web of Science ®Google Scholar
• Narayana A, Golfinos JG, Fischer I, Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 2008;72(2):383-9
   PubMed Web of Science ®Google Scholar
• Velenik V, Ocvirk J, Music M, Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol 2011;6:105
   PubMed Web of Science ®Google Scholar
• Caram MV, Schuetze SM. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. J Surg Oncol 2011;104(8):888-95
   PubMed Web of Science ®Google Scholar
• Vazquez S, Leon L, Fernandez O, Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma. Adv Ther 2012;29(3):202-17
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329-38
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
   PubMed Web of Science ®Google Scholar
• Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol 2012;27(5):862-72
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Tugues S, Koch S, Gualandi L, Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32(2):88-111
   PubMed Web of Science ®Google Scholar
• Zhao W, Gu YH, Song R, Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 2008;22(6):1226-33
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14(20):6674-82
   PubMed Web of Science ®Google Scholar
• Di Fiore F, Rigal O, Menager C, Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer 2011;105(12):1811-13
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Eisen T, Fishman M, Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011;78(1):24-32
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73
   PubMed Web of Science ®Google Scholar
• Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007;18(6):1117
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9
   PubMed Web of Science ®Google Scholar
• Willett CG, Duda DG, di Tomaso E, Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009;27(18):3020-6
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhong W, Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 2009;19(5):338-43
   PubMed Web of Science ®Google Scholar
• Laurent J, Touvrey C, Botta F, Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. Int J Dev Biol 2011;55(4-5):527-34
   PubMed Web of Science ®Google Scholar
• Fakhrejahani E, Toi M. Tumor angiogenesis: pericytes and maturation are not to be ignored. J Oncol 2012;2012:261750
   PubMedGoogle Scholar
• Helfrich I, Schadendorf D. Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance? Mol Oncol 2011;5(2):137-49
   PubMed Web of Science ®Google Scholar
• Huang J, Soffer SZ, Kim ES, Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2004;2(1):36-42
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Kim J, Ozawa T, Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2(4):306-14
   PubMed Web of Science ®Google Scholar
• Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26(3-4):489-502
   PubMed Web of Science ®Google Scholar
• Winkler F, Kienast Y, Fuhrmann M, Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis. Glia 2009;57(12):1306-15
   PubMed Web of Science ®Google Scholar
• Mandelcorn ED, Palestine AG, Dubovy S, Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab. J Ophthal Inflamm Infect 2011;1(1):35-8
   Google Scholar
• Maniotis AJ, Folberg R, Hess A, Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155(3):739-52
   PubMed Web of Science ®Google Scholar
• Shirakawa K, Kobayashi H, Sobajima J, Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res 2003;5(3):136-9
   PubMed Web of Science ®Google Scholar
• Chung LW, Huang WC, Sung SY, Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer 2006;5(2):162-70
   PubMed Web of Science ®Google Scholar
• Guzman G, Cotler SJ, Lin AY, A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med 2007;131(12):1776-81
   PubMed Web of Science ®Google Scholar
• Liu XM, Zhang QP, Mu YG, Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol 2011;105(2):173-9
   PubMed Web of Science ®Google Scholar
• Mihic-Probst D, Ikenberg K, Tinguely M, Tumor cell plasticity and angiogenesis in human melanomas. PLoS One 2012;7(3):e33571
   PubMedGoogle Scholar
• Soda Y, Marumoto T, Friedmann-Morvinski D, Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 2011;108(11):4274-80
   PubMed Web of Science ®Google Scholar
• Hackam DG. Translating animal research into clinical benefit. BMJ 2007;334(7586):163-4
   PubMed Web of Science ®Google Scholar
• Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA 2006;296(14):1731-2
   PubMed Web of Science ®Google Scholar
• Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008;13(1-2):30-7
   PubMed Web of Science ®Google Scholar
• Van Dyke T. Finding the tumor copycat: approximating a human cancer. Nat Med 2010;16(9):976-7
   PubMedGoogle Scholar
• Olive KP, Jacobetz MA, Davidson CJ, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324(5933):1457-61
   PubMed Web of Science ®Google Scholar
• Desai KV, Xiao N, Wang W, Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 2002;99(10):6967-72
   PubMed Web of Science ®Google Scholar
• Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nat Med 2010;16(9):974-5
   PubMedGoogle Scholar
• Senan S, Smit EF. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 2007;12(4):465-77
   PubMed Web of Science ®Google Scholar
• Adjei AA. What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J Clin Oncol 2006;24(25):4054-5
   PubMed Web of Science ®Google Scholar
• Meluch AA, Shipley D, Waterhouse DM, High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma (RCC): a Sarah Cannon Research Institute phase II trial. in 2011 ASCO Annual Meeting. J Clin Oncol 2011;29(suppl):abstr e15101
   PubMedGoogle Scholar
• Su Y, Yang WB, Li S, Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7(4):e35629
   PubMedGoogle Scholar
• Donate F, Parry GC, Shaked Y, Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res 2008;14(7):2137-44
   PubMed Web of Science ®Google Scholar
• Celik I, Surucu O, Dietz C, Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 2005;65(23):11044-50
   PubMed Web of Science ®Google Scholar
• Levashova Z, Backer M, Hamby CV, Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med 2010;51(6):959-66
   PubMed Web of Science ®Google Scholar
• Nagengast WB, Lub-de Hooge MN, Oosting SF, VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 2011;71(1):143-53
   PubMed Web of Science ®Google Scholar
• Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 2011;81(10):1183-91
   PubMed Web of Science ®Google Scholar
• Wolter P, Beuselinck B, Pans S, Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 2009;48(4):621-4
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70(10):779-87
   PubMed Web of Science ®Google Scholar
• di Tomaso E, Snuderl M, Kamoun WS, Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 2011;71(1):19-28
   PubMed Web of Science ®Google Scholar
• Miles D, Harbeck N, Escudier B, Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011;29(1):83-8
   PubMed Web of Science ®Google Scholar
• Grothey A, Sugrue MM, Purdie DM, Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26(33):5326-34
   PubMed Web of Science ®Google Scholar
• Cohn AL, Bekaii-Saab T, Bendell JC, Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol 2010;28(15s):abstr 3596
   Google Scholar
• Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8(4):210-21
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13
   PubMed Web of Science ®Google Scholar
• Kienast Y, von Baumgarten L, Fuhrmann M, Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010;16(1):116-22
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O'Connell MJ, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29(1):11-16
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Gorlia T, Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer 2012;48(6):896-903
   PubMed Web of Science ®Google Scholar
• Franceschi E, Brandes AA. Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe? Expert Rev Anticancer Ther 2011;11(5):657-60
   PubMed Web of Science ®Google Scholar
• Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008;13(Suppl 2):19-21
   PubMed Web of Science ®Google Scholar
• Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009;27(17):2874-80
   PubMed Web of Science ®Google Scholar
• Reardon DA, Galanis E, DeGroot JF, Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 2011;13(3):353-61
   PubMed Web of Science ®Google Scholar
• Lamborn KR, Yung WK, Chang SM, Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10(2):162-70
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-59
   PubMed Web of Science ®Google Scholar
• Menakuru SR, Brown NJ, Staton CA, Angiogenesis in pre-malignant conditions. Br J Cancer 2008;99(12):1961-6
   PubMed Web of Science ®Google Scholar
• Staton CA, Brown NJ, Reed MW. Current status and future prospects for anti-angiogenic therapies in cancer. Expert Opin Drug Discov 2009;4(9):961-79
   PubMed Web of Science ®Google Scholar
• Oklu R, Walker TG, Wicky S, Angiogenesis and current antiangiogenic strategies for the treatment of cancer. J Vasc Interv Radiol 2010;21(12):1791-805; quiz 1806
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17(11):1359-70
   PubMed Web of Science ®Google Scholar
• Hua H, Li M, Luo T, Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011;68(23):3853-68
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, Boehm T, Shing Y, Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88(2):277-85
   PubMed Web of Science ®Google Scholar
• Thomas JP, Arzoomanian RZ, Alberti D, Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21(2):223-31
   PubMed Web of Science ®Google Scholar
• Eder JP Jr, Supko JG, Clark JW, Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20(18):3772-84
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hess KR, Tran HT, Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20(18):3792-803
   PubMed Web of Science ®Google Scholar
• Wang J, Sun Y, Liu Y, Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2005;8(4):283-90
   PubMedGoogle Scholar
• Han B, Xiu Q, Wang H, A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 2011;6(6):1104-9
   PubMed Web of Science ®Google Scholar
• Sparano JA, Bernardo P, Stephenson P, Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004;22(23):4683-90
   PubMed Web of Science ®Google Scholar
• Hirte H, Vergote IB, Jeffrey JR, A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 2006;102(2):300-8
   PubMed Web of Science ®Google Scholar
• Moore MJ, Hamm J, Dancey J, Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21(17):3296-302
   PubMed Web of Science ®Google Scholar
• Rigas JR, Denham CA, Rinaldi DA, Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. in 2003 ASCO Annual Meeting. Proc Am Soc Clin Oncol 2003;22:abstr 2525
   Google Scholar
• Alva A, Slovin S, Daignault S, Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 2012;30(2):749-57
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26(34):5610-17
   PubMed Web of Science ®Google Scholar
• Peeters M, Price T, Van Laethem JL. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 2009;14(1):29-39
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Lang I, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011-19
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22(7):1535-46
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA, Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol 2004;22(16):3238-47
   PubMed Web of Science ®Google Scholar
• Townsley CA, Major P, Siu LL, Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006;94(8):1136-43
   PubMed Web of Science ®Google Scholar
• Gordon AN, Finkler N, Edwards RP, Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005;15(5):785-92
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77-85
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11(6):521-9
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(15):1960-6
   PubMed Web of Science ®Google Scholar
• Hwang IG, Jang JS, Oh SY, A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs 2012. PMID: 22302349. [Epub ahead of print]
   Web of Science ®Google Scholar
• Pan Q, Chanthery Y, Liang WC, Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007;11(1):53-67
   PubMed Web of Science ®Google Scholar
• Saltz LB, Lenz HJ, Kindler HL, Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25(29):4557-61
   PubMed Web of Science ®Google Scholar
• Herbst RS, O'Neill VJ, Fehrenbacher L, Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25(30):4743-50
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360(6):563-72
   PubMed Web of Science ®Google Scholar
• Laschke MW, Elitzsch A, Vollmar B, Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006;21(1):262-8
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Eschbach C, A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22(6):1374-81
   PubMed Web of Science ®Google Scholar
• Altorki N, Lane ME, Bauer T, Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010;28:3131-7
   PubMed Web of Science ®Google Scholar
• Slamon D, Gomez HL, Kabbinavar FF, Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 2008;26:1016
   PubMed Web of Science ®Google Scholar
• Wong CS, Sceneay J, House CM, Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy. Cancer Res 2012;72(7):1694-704
   PubMed Web of Science ®Google Scholar
• Shiau AL, Shen YT, Hsieh JL, Scutellaria barbata inhibits angiogenesis through downregulation of HIF-1 alpha in lung tumor. Environ Toxicol 2012. PMID: 22331677. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Van der Veldt AA, Lubberink M, Bahce I, Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012;21(1):82-91
   PubMed Web of Science ®Google Scholar
• Sorensen AG, Batchelor TT, Zhang WT, A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009;69(13):5296-300
   PubMed Web of Science ®Google Scholar
• St Croix B, Rago C, Velculescu V, Genes expressed in human tumor endothelium. Science 2000;289(5482):1197-202
   PubMed Web of Science ®Google Scholar
• MacFadyen J, Savage K, Wienke D, Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr Patterns 2007;7(3):363-9
   PubMed Web of Science ®Google Scholar
• Lee HK, Bae HR, Park HK, Cloning, characterization and neuronal expression profiles of tumor endothelial marker 7 in the rat brain. Brain Res Mol Brain Res 2005;136(1-2):189-98
   PubMedGoogle Scholar
• Halder C, Ossendorf C, Maran A, Preferential expression of the secreted and membrane forms of tumor endothelial marker 7 transcripts in osteosarcoma. Anticancer Res 2009;29(11):4317-22
   PubMed Web of Science ®Google Scholar
• Seaman S, Stevens J, Yang MY, Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007;11(6):539-54
   PubMed Web of Science ®Google Scholar
• Oh P, Li Y, Yu J, Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004;429(6992):629-35
   PubMed Web of Science ®Google Scholar
• Legg JA, Herbert JM, Clissold P, Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis 2008;11(1):13-21
   PubMed Web of Science ®Google Scholar
• Mura M, Swain RK, Zhuang X, Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 2012;31(3):293-305
   PubMed Web of Science ®Google Scholar
• Jubb AM, Hurwitz HI, Bai W, Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24(2):217-27
   PubMed Web of Science ®Google Scholar
• Jubb AM, Miller KD, Rugo HS, Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011;17(2):372-81
   PubMed Web of Science ®Google Scholar
• Sessa C, Guibal A, Del Conte G, Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008;5(7):378-91
   PubMedGoogle Scholar
• Dellapasqua S, Bertolini F, Bagnardi V, Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26(30):4899-905
   PubMed Web of Science ®Google Scholar
• Duda DG, Cohen KS, di Tomaso E, Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 2006;24(9):1449-53
   PubMed Web of Science ®Google Scholar
• Zhang D, Hedlund EM, Lim S, Chen F, Zhang Y, Sun B, Cao Y. Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc Natl Acad Sci U S A 2008;105(47):18513-8
   PubMedGoogle Scholar
• Zee YK, Murukesh N, Kumaran G, Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC). in 2010 ASCO Annual Meeting. J Clin Oncol 2010;28(suppl):abstr e13580
   Google Scholar
• Horsley L, Marti K, Jayson GC. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol 2012;8(3):283-93
   PubMed Web of Science ®Google Scholar
• Terasawa T, Nihashi T, Hotta T, 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008;49(1):13-21
   PubMed Web of Science ®Google Scholar
• Niu G, Chen X. PET Imaging of Angiogenesis. PET Clin 2009;4(1):17-38
   PubMedGoogle Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-19
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137-43
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S, Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28(13):2144-50
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28(22):3617-22
   PubMed Web of Science ®Google Scholar
• Hapani S, Sher A, Chu D, Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010;79(1-2):27-38
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300(19):2277-85
   PubMed Web of Science ®Google Scholar
• Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10(6):559-68
   PubMed Web of Science ®Google Scholar
• Burki F, Badie K, Bartoli P, Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. Br J Clin Pharmacol 2008;65(5):793-4
   PubMed Web of Science ®Google Scholar
• Seet RC, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 2012;105(1):69-75
   PubMed Web of Science ®Google Scholar